Profund Advisors LLC trimmed its holdings in shares of Haemonetics Corporation (NYSE:HAE) by 11.8% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 10,276 shares of the medical instruments supplier’s stock after selling 1,372 shares during the period. Profund Advisors LLC’s holdings in Haemonetics Corporation were worth $406,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Shine Investment Advisory Services Inc. purchased a new position in shares of Haemonetics Corporation during the second quarter valued at approximately $132,000. Riverhead Capital Management LLC lifted its holdings in shares of Haemonetics Corporation by 79.3% during the second quarter. Riverhead Capital Management LLC now owns 3,407 shares of the medical instruments supplier’s stock valued at $135,000 after purchasing an additional 1,507 shares during the last quarter. Pacad Investment Ltd. purchased a new position in shares of Haemonetics Corporation during the second quarter valued at approximately $174,000. Ameritas Investment Partners Inc. purchased a new position in shares of Haemonetics Corporation during the first quarter valued at approximately $179,000. Finally, Amalgamated Bank lifted its holdings in shares of Haemonetics Corporation by 5.7% during the second quarter. Amalgamated Bank now owns 7,322 shares of the medical instruments supplier’s stock valued at $289,000 after purchasing an additional 392 shares during the last quarter.

Several equities analysts have recently issued reports on HAE shares. BidaskClub lowered shares of Haemonetics Corporation from a “hold” rating to a “sell” rating in a report on Friday, June 23rd. Zacks Investment Research upgraded shares of Haemonetics Corporation from a “sell” rating to a “hold” rating in a report on Wednesday, July 12th. JMP Securities upgraded shares of Haemonetics Corporation from a “market perform” rating to an “outperform” rating and set a $50.00 target price for the company in a report on Thursday, July 13th. Jefferies Group LLC reiterated a “buy” rating and set a $48.00 target price on shares of Haemonetics Corporation in a report on Thursday, July 27th. Finally, Barrington Research upgraded shares of Haemonetics Corporation from a “market perform” rating to an “outperform” rating and set a $48.00 target price for the company in a report on Tuesday, August 8th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $41.67.

Haemonetics Corporation (NYSE HAE) opened at 45.75 on Thursday. The stock has a market capitalization of $2.41 billion, a price-to-earnings ratio of 594.16 and a beta of 0.87. The company has a 50-day moving average of $42.78 and a 200-day moving average of $41.29. Haemonetics Corporation has a one year low of $32.76 and a one year high of $46.85.

Haemonetics Corporation (NYSE:HAE) last posted its earnings results on Monday, August 7th. The medical instruments supplier reported $0.33 EPS for the quarter, beating the Zacks’ consensus estimate of $0.31 by $0.02. Haemonetics Corporation had a net margin of 0.48% and a return on equity of 11.07%. The company had revenue of $211.00 million during the quarter, compared to analysts’ expectations of $211.29 million. During the same quarter in the prior year, the company posted $0.25 earnings per share. Haemonetics Corporation’s revenue for the quarter was up .5% compared to the same quarter last year. On average, equities analysts forecast that Haemonetics Corporation will post $1.60 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another publication, it was stolen and reposted in violation of United States & international copyright and trademark laws. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/10/05/profund-advisors-llc-sells-1372-shares-of-haemonetics-corporation-hae.html.

Haemonetics Corporation Company Profile

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Corporation (NYSE:HAE).

Institutional Ownership by Quarter for Haemonetics Corporation (NYSE:HAE)

Receive News & Stock Ratings for Haemonetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corporation and related stocks with our FREE daily email newsletter.